09.17.18
BIA Separations, a biochromatography development and manufacturing company, has expanded its services with the opening of a new upstream processing (USP) laboratory.
The investment in the new facility supports demand for services that optimize the critical interface between upstream and downstream processing for the robust and scalable production of complex molecules and biologics, such as viral vectors, phages, and exosomes. The new USP facility will provide biopharmaceutical manufacturing processing in an integrated way, with coordination of critical steps, including upstream choice of cell line; source and supply of materials; bioreactor processing parameters and the consequential impact on downstream product purification; formulation; and stability profiles.
Aleš Štrancar, chief executive officer of BIA Separations said, “This month BIA Separations celebrates our 20th Anniversary and we are delighted to mark it with the opening of this new USP facility. Alongside our many years’ experience and expertise in understanding and controlling bioprocesses, we now have the capability to manage the interface between upstream and downstream processes, which is key for complex biologics production.”
The investment in the new facility supports demand for services that optimize the critical interface between upstream and downstream processing for the robust and scalable production of complex molecules and biologics, such as viral vectors, phages, and exosomes. The new USP facility will provide biopharmaceutical manufacturing processing in an integrated way, with coordination of critical steps, including upstream choice of cell line; source and supply of materials; bioreactor processing parameters and the consequential impact on downstream product purification; formulation; and stability profiles.
Aleš Štrancar, chief executive officer of BIA Separations said, “This month BIA Separations celebrates our 20th Anniversary and we are delighted to mark it with the opening of this new USP facility. Alongside our many years’ experience and expertise in understanding and controlling bioprocesses, we now have the capability to manage the interface between upstream and downstream processes, which is key for complex biologics production.”
